Search

Your search keyword '"Leguy‐Seguin, Vanessa"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Leguy‐Seguin, Vanessa" Remove constraint Author: "Leguy‐Seguin, Vanessa"
39 results on '"Leguy‐Seguin, Vanessa"'

Search Results

2. Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL)

3. Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT

4. Clinical phenotype of adult-onset systemic histiocytosis harboring BRAF in-frame deletions

5. Mass cytometry reveals atypical immune profile notably impaired maturation of memory CD4 T with Gb3‐related CD27 expression in CD4 T cells in Fabry disease.

8. Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial

10. B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia

11. Pro-angiogenic changes of Thelper lymphocytes in hereditary hemorrhagic telangiectasia.

12. Impact of BRAFV600E mutation on aggressiveness and outcomes in adult clonal histiocytosis.

13. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia

14. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY

15. Additional file 4 of Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT

16. Iodoacetamide blank compensation in FXIII functional assays: Is it still necessary?

17. Development and validation of a quality of life measurement scale specific to Hereditary Hemorrhagic Telangiectasia: The QoL-HHT

18. Sphingosine-1-Phosphate Levels Are Higher in Male Patients with Non-Classic Fabry Disease

21. A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease

22. Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease

23. Coagulation parameters in adults patients with type 1 Gaucher disease

24. Natural history of untreated patients with type 1 Gaucher disease

25. French experience in the evaluation of plasma CCL18 levels in Gaucher Disease type 1

26. Untreated patients with type 1 Gaucher disease: who are they? Resultas from the Gaucher Non-Treated study (GANT study)

28. Coagulation Parameters in Adult Patients With Type-1 Gaucher Disease

29. Venous thromboembolic events during warm autoimmune hemolytic anemia

30. Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement

32. Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability

33. The French Gaucher Disease Registry: Clinical characteristics, complications and treatment of 616 patients

34. Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia

35. Severe Aplastic Anemia Associated With Eosinophilic Fasciitis

36. Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry.

37. Neuropsychological profile of French adults with early-treated phenylketonuria: a multicenter study.

38. Impact of BRAF V600E mutation on aggressiveness and outcomes in adult clonal histiocytosis.

39. [Severe thrombocytopenia and mild leucopenia associated with deferasirox therapy].

Catalog

Books, media, physical & digital resources